China Dasheng Biotechnology Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on China Dasheng Biotechnology's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Chemicals Industry Growth | 12.9% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 31 Mar 2009 |
Recent past performance updates
No updates
Recent updates
In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, China Dasheng Biotechnology has not provided sufficient past data to assess its track record.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.
Show sectionRevenue & Expenses BreakdownBeta
How China Dasheng Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 09 | 21 | 6 | 3 | 0 |
Quality Earnings: Insufficient data to determine if CDBT has high quality earnings.
Growing Profit Margin: Insufficient data to determine if CDBT's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CDBT's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare CDBT's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if CDBT's earnings growth over the past year exceeded the Chemicals industry average.
Return on Equity
High ROE: CDBT has a negative Return on Equity (0%), as it is currently unprofitable.